HelpAcademyLoginJoin us as a Member

Company Screener

Filter healthcare companies on facts HealthTrade stores: drugs by stage, published catalysts, reported SEC financials and Form 4 insider transactions. Every value shows its period and source, and a value that isn't on record reads “Not reported”.

Catalysts one by one: Catalyst Explorer · Every company: Companies

Preset screens

Type your question

Sign in to have Triage turn a sentence into screener filters. You check the filters before anything runs.

Saved company screens

Sign in to save these filters as a company screen.

Results

25 of 1,547 companies, sorted by name

Companies matching the screen, with each value's period and source
CompanyBy stageNext catalystCash and cash equivalentsRevenueResearch and development expenseNet income (loss)Estimated runwayInsiders, last 90 days
10X Capital Venture Acquisition Corp. IIINo drugs on recordNone in the window$646,847At 30 Sep 202310-Q filed 27 Nov 2023 for 10X Capital Venture Acquisition Corp. III on sec.gov (opens in a new tab)Not reportedNot reported−$2.29M1 Jul 2023 to 30 Sep 202310-Q filed 27 Nov 2023 for 10X Capital Venture Acquisition Corp. III on sec.gov (opens in a new tab)Not reportedNot reported
2seventy bio, Inc.No drugs on recordNone in the window$92.36MAt 31 Mar 202510-Q filed 7 May 2025 for 2seventy bio, Inc. on sec.gov (opens in a new tab)$22.94M1 Jan 2025 to 31 Mar 202510-Q filed 7 May 2025 for 2seventy bio, Inc. on sec.gov (opens in a new tab)$5.4M1 Jan 2025 to 31 Mar 202510-Q filed 7 May 2025 for 2seventy bio, Inc. on sec.gov (opens in a new tab)$482,0001 Jan 2025 to 31 Mar 202510-Q filed 7 May 2025 for 2seventy bio, Inc. on sec.gov (opens in a new tab) Not estimated: no net loss in that quarter Estimated from net loss, at 31 Mar 2025SEC filing for 2seventy bio, Inc. (opens in a new tab) 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for 2seventy bio, Inc. on sec.gov (opens in a new tab)
3M COMMMNo drugs on recordNone in the window$4.84BAt 30 Sep 202610-Q filed 20 Oct 2026 for 3M CO on sec.gov (opens in a new tab)$6.58B1 Jul 2026 to 30 Sep 202610-Q filed 20 Oct 2026 for 3M CO on sec.gov (opens in a new tab)$700M1 Jan 2024 to 31 Dec 202410-K filed 5 Feb 2025 for 3M CO on sec.gov (opens in a new tab)$1.37B1 Jul 2026 to 30 Sep 202610-Q filed 20 Oct 2026 for 3M CO on sec.gov (opens in a new tab) Not estimated: no net loss in that quarter Estimated from net loss, at 30 Sep 2026SEC filing for 3M CO (opens in a new tab) 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for 3M CO on sec.gov (opens in a new tab)
4D Molecular Therapeutics, Inc.FDMT Phase 3: 1 1 not yet reviewedNone in the window$70.37MAt 30 Jun 202610-Q filed 13 Aug 2026 for 4D Molecular Therapeutics, Inc. on sec.gov (opens in a new tab)$3.78M1 Apr 2026 to 30 Jun 202610-Q filed 13 Aug 2026 for 4D Molecular Therapeutics, Inc. on sec.gov (opens in a new tab)$68.28M1 Apr 2026 to 30 Jun 202610-Q filed 13 Aug 2026 for 4D Molecular Therapeutics, Inc. on sec.gov (opens in a new tab)−$72.94M1 Apr 2026 to 30 Jun 202610-Q filed 13 Aug 2026 for 4D Molecular Therapeutics, Inc. on sec.gov (opens in a new tab)Not reported 0 purchases · 6 sales Open-market, Form 4Latest Form 4 for 4D Molecular Therapeutics, Inc. on sec.gov (opens in a new tab)
4Front Ventures Corp.No drugs on recordNone in the window$1.25MAt 30 Sep 202410-Q filed 14 Nov 2024 for 4Front Ventures Corp. on sec.gov (opens in a new tab)$17.13M1 Jul 2024 to 30 Sep 202410-Q filed 14 Nov 2024 for 4Front Ventures Corp. on sec.gov (opens in a new tab)Not reported−$6.4M1 Jul 2024 to 30 Sep 202410-Q filed 14 Nov 2024 for 4Front Ventures Corp. on sec.gov (opens in a new tab)Not reported 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for 4Front Ventures Corp. on sec.gov (opens in a new tab)
60 DEGREES PHARMACEUTICALS, INC.SXTP, SXTPWNo drugs on recordNone in the window$1.02MAt 30 Jun 202610-Q filed 14 Aug 2026 for 60 DEGREES PHARMACEUTICALS, INC. on sec.gov (opens in a new tab)$207,8981 Apr 2026 to 30 Jun 202610-Q filed 14 Aug 2026 for 60 DEGREES PHARMACEUTICALS, INC. on sec.gov (opens in a new tab)$598,6531 Apr 2026 to 30 Jun 202610-Q filed 14 Aug 2026 for 60 DEGREES PHARMACEUTICALS, INC. on sec.gov (opens in a new tab)−$2.26M1 Apr 2026 to 30 Jun 202610-Q filed 14 Aug 2026 for 60 DEGREES PHARMACEUTICALS, INC. on sec.gov (opens in a new tab)Not reported 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for 60 DEGREES PHARMACEUTICALS, INC. on sec.gov (opens in a new tab)
89bio, Inc. Phase 3: 1 1 not yet reviewedNone in the window$129.08MAt 30 Jun 202510-Q filed 8 Aug 2025 for 89bio, Inc. on sec.gov (opens in a new tab)Not reported$103.9M1 Apr 2025 to 30 Jun 202510-Q filed 8 Aug 2025 for 89bio, Inc. on sec.gov (opens in a new tab)−$111.5M1 Apr 2025 to 30 Jun 202510-Q filed 8 Aug 2025 for 89bio, Inc. on sec.gov (opens in a new tab)Not reported 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for 89bio, Inc. on sec.gov (opens in a new tab)
99 Acquisition Group Inc.No drugs on recordNone in the window$109At 31 Mar 202410-Q filed 21 May 2024 for 99 Acquisition Group Inc. on sec.gov (opens in a new tab)Not reportedNot reported$365,3321 Jan 2024 to 31 Mar 202410-Q filed 21 May 2024 for 99 Acquisition Group Inc. on sec.gov (opens in a new tab)Not reportedNot reported
Aardvark Therapeutics, Inc.AARDNo drugs on recordNone in the window$73.85MAt 30 Jun 202610-Q filed 11 Aug 2026 for Aardvark Therapeutics, Inc. on sec.gov (opens in a new tab)$01 Jan 2026 to 31 Mar 202610-Q filed 7 May 2026 for Aardvark Therapeutics, Inc. on sec.gov (opens in a new tab)$10.46M1 Apr 2026 to 30 Jun 202610-Q filed 11 Aug 2026 for Aardvark Therapeutics, Inc. on sec.gov (opens in a new tab)−$14.39M1 Apr 2026 to 30 Jun 202610-Q filed 11 Aug 2026 for Aardvark Therapeutics, Inc. on sec.gov (opens in a new tab)Not reported 0 purchases · 2 sales Open-market, Form 4Latest Form 4 for Aardvark Therapeutics, Inc. on sec.gov (opens in a new tab)
ABBOTT LABORATORIESABT Phase 3: 1 1 not yet reviewedNone in the window$4.05BAt 30 Sep 202610-Q filed 4 Nov 2026 for ABBOTT LABORATORIES on sec.gov (opens in a new tab)$13.01B1 Jul 2026 to 30 Sep 202610-Q filed 4 Nov 2026 for ABBOTT LABORATORIES on sec.gov (opens in a new tab)$920M1 Jul 2026 to 30 Sep 202610-Q filed 4 Nov 2026 for ABBOTT LABORATORIES on sec.gov (opens in a new tab)$920M1 Jul 2026 to 30 Sep 202610-Q filed 4 Nov 2026 for ABBOTT LABORATORIES on sec.gov (opens in a new tab) Not estimated: no net loss in that quarter Estimated from net loss, at 30 Sep 2026SEC filing for ABBOTT LABORATORIES (opens in a new tab) 0 purchases · 3 sales Open-market, Form 4Latest Form 4 for ABBOTT LABORATORIES on sec.gov (opens in a new tab)
AbbVie Inc.ABBVTracked Phase 2/3: 3 · Phase 3: 14 · Approved: 14 31 not yet reviewedNone in the window$10.77BAt 30 Sep 202610-Q filed 3 Nov 2026 for AbbVie Inc. on sec.gov (opens in a new tab)$17.4B1 Jul 2026 to 30 Sep 202610-Q filed 3 Nov 2026 for AbbVie Inc. on sec.gov (opens in a new tab)$2.57B1 Jul 2026 to 30 Sep 202610-Q filed 3 Nov 2026 for AbbVie Inc. on sec.gov (opens in a new tab)$4.22B1 Jul 2026 to 30 Sep 202610-Q filed 3 Nov 2026 for AbbVie Inc. on sec.gov (opens in a new tab) Not estimated: no net loss in that quarter Estimated from net loss, at 30 Sep 2026SEC filing for AbbVie Inc. (opens in a new tab) 0 purchases · 1 sale Open-market, Form 4Latest Form 4 for AbbVie Inc. on sec.gov (opens in a new tab)
AbCellera Biologics Inc.ABCLNo drugs on recordNone in the window$163.8MAt 30 Sep 202610-Q filed 9 Nov 2026 for AbCellera Biologics Inc. on sec.gov (opens in a new tab)$10.64M1 Jul 2026 to 30 Sep 202610-Q filed 9 Nov 2026 for AbCellera Biologics Inc. on sec.gov (opens in a new tab)$43.54M1 Jul 2026 to 30 Sep 202610-Q filed 9 Nov 2026 for AbCellera Biologics Inc. on sec.gov (opens in a new tab)−$40.76M1 Jul 2026 to 30 Sep 202610-Q filed 9 Nov 2026 for AbCellera Biologics Inc. on sec.gov (opens in a new tab)Not reported 2 purchases · 0 sales Open-market, Form 4Latest Form 4 for AbCellera Biologics Inc. on sec.gov (opens in a new tab)
ABEONA THERAPEUTICS INC.ABEONo drugs on recordNone in the window$66.28MAt 30 Sep 202610-Q filed 9 Nov 2026 for ABEONA THERAPEUTICS INC. on sec.gov (opens in a new tab)$13.49M1 Jul 2026 to 30 Sep 202610-Q filed 9 Nov 2026 for ABEONA THERAPEUTICS INC. on sec.gov (opens in a new tab)$3.67M1 Jul 2026 to 30 Sep 202610-Q filed 9 Nov 2026 for ABEONA THERAPEUTICS INC. on sec.gov (opens in a new tab)−$4.81M1 Jul 2026 to 30 Sep 202610-Q filed 9 Nov 2026 for ABEONA THERAPEUTICS INC. on sec.gov (opens in a new tab) About 28.1 quarters Estimated from net loss, at 30 Sep 2026SEC filing for ABEONA THERAPEUTICS INC. (opens in a new tab) 0 purchases · 5 sales Open-market, Form 4Latest Form 4 for ABEONA THERAPEUTICS INC. on sec.gov (opens in a new tab)
Abivax S.A.ABVX, AAVXF Phase 3: 1 1 not yet reviewedNone in the window516,685,000 EURAt 31 Dec 202520-F filed 23 Mar 2026 for Abivax S.A. on sec.gov (opens in a new tab)Not reported177,761,000 EUR1 Jan 2025 to 31 Dec 202520-F filed 23 Mar 2026 for Abivax S.A. on sec.gov (opens in a new tab)−336,102,000 EUR1 Jan 2025 to 31 Dec 202520-F filed 23 Mar 2026 for Abivax S.A. on sec.gov (opens in a new tab)Not reportedNot reported
Abpro Holdings, Inc.ABPO, ABPWWNo drugs on recordNone in the window$4.24MAt 30 Jun 202610-Q filed 14 Aug 2026 for Abpro Holdings, Inc. on sec.gov (opens in a new tab)$183,0001 Jan 2024 to 31 Dec 202410-K filed 15 Apr 2025 for Abpro Holdings, Inc. on sec.gov (opens in a new tab)$9,0001 Apr 2026 to 30 Jun 202610-Q filed 14 Aug 2026 for Abpro Holdings, Inc. on sec.gov (opens in a new tab)−$940,0001 Apr 2026 to 30 Jun 202610-Q filed 14 Aug 2026 for Abpro Holdings, Inc. on sec.gov (opens in a new tab)Not reported 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for Abpro Holdings, Inc. on sec.gov (opens in a new tab)
Absci CorpABSINo drugs on recordNone in the window$107.87MAt 30 Jun 202610-Q filed 11 Aug 2026 for Absci Corp on sec.gov (opens in a new tab)$318,0001 Apr 2026 to 30 Jun 202610-Q filed 11 Aug 2026 for Absci Corp on sec.gov (opens in a new tab)$22.62M1 Apr 2026 to 30 Jun 202610-Q filed 11 Aug 2026 for Absci Corp on sec.gov (opens in a new tab)−$33.21M1 Apr 2026 to 30 Jun 202610-Q filed 11 Aug 2026 for Absci Corp on sec.gov (opens in a new tab) About 6.1 quarters Estimated from net loss, at 30 Jun 2026SEC filing for Absci Corp (opens in a new tab) 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for Absci Corp on sec.gov (opens in a new tab)
ABVC BIOPHARMA, INC.ABVC, ECOCNo drugs on recordNone in the window$11,294At 30 Sep 202610-Q filed 10 Nov 2026 for ABVC BIOPHARMA, INC. on sec.gov (opens in a new tab)$296,0001 Jan 2025 to 31 Dec 202510-K filed 3 Mar 2026 for ABVC BIOPHARMA, INC. on sec.gov (opens in a new tab)$18,0401 Jul 2026 to 30 Sep 202610-Q filed 10 Nov 2026 for ABVC BIOPHARMA, INC. on sec.gov (opens in a new tab)$1.15M1 Jul 2026 to 30 Sep 202610-Q filed 10 Nov 2026 for ABVC BIOPHARMA, INC. on sec.gov (opens in a new tab) Not estimated: no net loss in that quarter Estimated from net loss, at 30 Sep 2026SEC filing for ABVC BIOPHARMA, INC. (opens in a new tab) 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for ABVC BIOPHARMA, INC. on sec.gov (opens in a new tab)
AC Immune SAACIUNo drugs on recordNone in the window26,795,000 CHFAt 31 Dec 202520-F filed 13 Mar 2026 for AC Immune SA on sec.gov (opens in a new tab)3,573,000 CHF1 Jan 2025 to 31 Dec 202520-F filed 13 Mar 2026 for AC Immune SA on sec.gov (opens in a new tab)56,436,000 CHF1 Jan 2025 to 31 Dec 202520-F filed 13 Mar 2026 for AC Immune SA on sec.gov (opens in a new tab)−70,447,000 CHF1 Jan 2025 to 31 Dec 202520-F filed 13 Mar 2026 for AC Immune SA on sec.gov (opens in a new tab)Not reported 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for AC Immune SA on sec.gov (opens in a new tab)
Acadia Healthcare Company, Inc.ACHCNo drugs on recordNone in the window$163.31MAt 30 Sep 202610-Q filed 4 Nov 2026 for Acadia Healthcare Company, Inc. on sec.gov (opens in a new tab)$895.31M1 Jul 2026 to 30 Sep 202610-Q filed 4 Nov 2026 for Acadia Healthcare Company, Inc. on sec.gov (opens in a new tab)Not reported$34.49M1 Jul 2026 to 30 Sep 202610-Q filed 4 Nov 2026 for Acadia Healthcare Company, Inc. on sec.gov (opens in a new tab) Not estimated: no net loss in that quarter Estimated from net loss, at 30 Sep 2026SEC filing for Acadia Healthcare Company, Inc. (opens in a new tab) 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for Acadia Healthcare Company, Inc. on sec.gov (opens in a new tab)
ACADIA PHARMACEUTICALS INCACAD Phase 3: 2 2 not yet reviewedNone in the window$322.37MAt 30 Sep 202610-Q filed 5 Nov 2026 for ACADIA PHARMACEUTICALS INC on sec.gov (opens in a new tab)$342.29M1 Jul 2026 to 30 Sep 202610-Q filed 5 Nov 2026 for ACADIA PHARMACEUTICALS INC on sec.gov (opens in a new tab)$76.28M1 Jul 2026 to 30 Sep 202610-Q filed 5 Nov 2026 for ACADIA PHARMACEUTICALS INC on sec.gov (opens in a new tab)$53.52M1 Jul 2026 to 30 Sep 202610-Q filed 5 Nov 2026 for ACADIA PHARMACEUTICALS INC on sec.gov (opens in a new tab) Not estimated: no net loss in that quarter Estimated from net loss, at 30 Sep 2026SEC filing for ACADIA PHARMACEUTICALS INC (opens in a new tab) 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for ACADIA PHARMACEUTICALS INC on sec.gov (opens in a new tab)
ACCENDRA HEALTH INCACHNo drugs on recordNone in the window$26.61MAt 30 Sep 202610-Q filed 6 Nov 2026 for ACCENDRA HEALTH INC on sec.gov (opens in a new tab)$601.78M1 Jul 2026 to 30 Sep 202610-Q filed 6 Nov 2026 for ACCENDRA HEALTH INC on sec.gov (opens in a new tab)$13M1 Jan 2024 to 31 Dec 202410-K filed 28 Feb 2025 for ACCENDRA HEALTH INC on sec.gov (opens in a new tab)−$19.7M1 Jul 2026 to 30 Sep 202610-Q filed 6 Nov 2026 for ACCENDRA HEALTH INC on sec.gov (opens in a new tab) About 1.4 quarters Estimated from net loss, at 30 Sep 2026SEC filing for ACCENDRA HEALTH INC (opens in a new tab) 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for ACCENDRA HEALTH INC on sec.gov (opens in a new tab)
ACCURAY INCARAYNo drugs on recordNone in the window$42.25MAt 30 Sep 202610-Q filed 6 Nov 2026 for ACCURAY INC on sec.gov (opens in a new tab)$86.52M1 Jul 2026 to 30 Sep 202610-Q filed 6 Nov 2026 for ACCURAY INC on sec.gov (opens in a new tab)$7.81M1 Jul 2026 to 30 Sep 202610-Q filed 6 Nov 2026 for ACCURAY INC on sec.gov (opens in a new tab)$10.13M1 Jul 2026 to 30 Sep 202610-Q filed 6 Nov 2026 for ACCURAY INC on sec.gov (opens in a new tab) Not estimated: no net loss in that quarter Estimated from net loss, at 30 Sep 2026SEC filing for ACCURAY INC (opens in a new tab) 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for ACCURAY INC on sec.gov (opens in a new tab)
Accustem Sciences Inc.ACUTNo drugs on recordNone in the window$12,928At 30 Jun 202610-Q filed 14 Aug 2026 for Accustem Sciences Inc. on sec.gov (opens in a new tab)$98,4001 Apr 2026 to 30 Jun 202610-Q filed 14 Aug 2026 for Accustem Sciences Inc. on sec.gov (opens in a new tab)$43,7121 Apr 2026 to 30 Jun 202610-Q filed 14 Aug 2026 for Accustem Sciences Inc. on sec.gov (opens in a new tab)−$252,5731 Apr 2026 to 30 Jun 202610-Q filed 14 Aug 2026 for Accustem Sciences Inc. on sec.gov (opens in a new tab) About 0.1 quarters Estimated from net loss, at 30 Jun 2026SEC filing for Accustem Sciences Inc. (opens in a new tab) 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for Accustem Sciences Inc. on sec.gov (opens in a new tab)
ACELYRIN, Inc.No drugs on recordNone in the window$58.27MAt 31 Mar 202510-Q filed 14 May 2025 for ACELYRIN, Inc. on sec.gov (opens in a new tab)Not reported$42.14M1 Jan 2025 to 31 Mar 202510-Q filed 14 May 2025 for ACELYRIN, Inc. on sec.gov (opens in a new tab)−$55.26M1 Jan 2025 to 31 Mar 202510-Q filed 14 May 2025 for ACELYRIN, Inc. on sec.gov (opens in a new tab)Not reported 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for ACELYRIN, Inc. on sec.gov (opens in a new tab)
Acer Therapeutics Inc. Phase 3: 1 1 not yet reviewedNone in the window$594,659At 30 Sep 202310-Q filed 20 Nov 2023 for Acer Therapeutics Inc. on sec.gov (opens in a new tab)$371,7901 Jul 2023 to 30 Sep 202310-Q filed 20 Nov 2023 for Acer Therapeutics Inc. on sec.gov (opens in a new tab)$1.52M1 Jul 2023 to 30 Sep 202310-Q filed 20 Nov 2023 for Acer Therapeutics Inc. on sec.gov (opens in a new tab)−$14.73M1 Jul 2023 to 30 Sep 202310-Q filed 20 Nov 2023 for Acer Therapeutics Inc. on sec.gov (opens in a new tab) About 0.0 quarters Estimated from net loss, at 30 Sep 2023SEC filing for Acer Therapeutics Inc. (opens in a new tab) 0 purchases · 0 sales Open-market, Form 4Latest Form 4 for Acer Therapeutics Inc. on sec.gov (opens in a new tab)

Catalysts follow the drug list's rule: editor-approved, not yet ended, and still scheduled or moved. Dates come from company and FDA disclosures and can change. Your plan covers catalysts in the next 30 days; Pro plans include every date.

Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice. Money filters compare US dollar values of the latest report; a company with no value, or one reported in another currency, counts as not reported and never as zero.

Estimated from net loss: cash and short-term investments at the last report, divided by that quarter's net loss (a quarter of the year's loss when only an annual figure was filed). Net loss is not the same as cash spent, so this is a rough estimate.

Counts of open-market purchases (Form 4 code P) and sales (code S) by company insiders, by transaction date, from the Form 4 filings HealthTrade stores. Not reported means no Form 4 transaction is on record for the company.

Every value is a stored record with its period and source: SEC filings, FDA, ClinicalTrials.gov or HealthTrade editors. No scores, ratings or rankings. Not investment advice.

Company data: SEC EDGAR and HealthTrade editors. FDA data provided by the U.S. Food and Drug Administration. Nothing here is investment advice.